Home Mass Torts Why Us FAQ Contact Get Pricing
$300M+Client Settlement Value
133,000+Qualified Leads Delivered
15+Years in Legal Marketing
100%Exclusive, Never Resold

Ozempic Lawsuit Leads & Lead Generation for Law Firms - Since 2009 ·

Ozempic Legal Leads That Survive the Court's New Standard

The GLP-1 litigation moved from volume to evidence. The federal court now requires objective diagnostic proof to keep a gastroparesis claim alive - and an unverified name is a file the MDL will throw out. As a dedicated Ozempic lawsuit lead generation partner, we deliver exclusive, pre-verified Ozempic lawsuit leads - Ozempic, Wegovy, Mounjaro and Zepbound claimants with gastroparesis or NAION vision loss - screened to the exact standard MDL 3094 and 3163 now demand. Qualified claimants matched to your criteria, or you don't pay.

133K+Leads Delivered
7–10Days to First Lead
15+Years Experience
Gastroparesis
NAION Vision Loss
Ileus & Bowel Obstruction
MDL 3094
MDL 3163
Scintigraphy-Verified
Semaglutide
Exclusive Leads
Gastroparesis
NAION Vision Loss
Ileus & Bowel Obstruction
MDL 3094
MDL 3163
Scintigraphy-Verified
Semaglutide
Exclusive Leads
Compliance & StandardsBuilt to protect your firm
ABA, HIPAA, TCPA Compliant ID Verified Litigator Scrub TrustedForm Phone Validation Email Validation Replacement Policy

From Inquiry to Filable File

How Every Ozempic Lead Is Built

We don't sell raw clicks. As a full-service Ozempic lawsuit lead generation partner, each Ozempic lawsuit mass tort case lead moves through four stages before it reaches your firm - exclusive, compliant, and screened to the standard that keeps the case alive.

Criteria Build

We map your docket strategy - gastroparesis vs. NAION, hospitalization thresholds, target states - into a custom intake script written for your firm.

Targeted Acquisition

National campaigns across medication-specific SEO and paid social reach the diabetes and weight-loss population. GLP-1 drugs were prescribed everywhere, so coverage is nationwide.

Verification

Lead Insight fraud scanning, live intake-agent screening to your criteria, third-party ID on SSN/address/DOB, and diagnostic-status capture on every file.

Exclusive Delivery

Compliant, CRM-integrated claimant files delivered to your firm only - with questionnaire and required forms attached. Real-time or live transfer to remove lag.

How claimants get qualified

Why This Is Your Moat

Every Lead, Screened to the Diagnosis That Holds Up

Here's the part most firms learn the expensive way. After the court's ruling, an unverified gastroparesis claim was immediately discounted - and with defense Daubert challenges testing the plaintiffs' experts, any case that can't show the science faces further pressure.

So we capture diagnostic posture before a lead ever reaches you. When you buy from us, you're not just buying a claimant - you're buying one already on the right side of the line the court drew.

A confirmed diagnosis is no longer a "nice to have." It is the difference between a file you can litigate and an intake hour you'll never get back.
Accepted Diagnostic Proof We Screen For
Gastric Emptying Study (Scintigraphy)The court's "gold standard" - a tagged meal tracked as it leaves the stomach. We confirm whether the claimant has it.
Wireless Motility Capsule (WMC)An accepted alternative measuring transit through the GI tract - captured and flagged in the file.
Gastric Emptying Breath TestThe third validated route to a defensible gastroparesis diagnosis under the MDL's order.
NAION Ophthalmologic ConfirmationFor vision-loss claims: formal diagnosis by an ophthalmologist or neuro-ophthalmologist, with mimics ruled out.
We capture diagnostic status at intake and flag it on every delivered file, so your team knows exactly what it's working with.

Marketing Solutions

Every Channel.
One Platform.

We are proud to offer a wide range of marketing options. Our services are fully customizable and tailored to your firm's needs.

Exclusive Web Leads

Inbound web leads generated for your firm alone — never resold or shared

Exclusive Live Transfers

Pre-screened claimants transferred live to your staff, ready to retain

Signed Retainers

Fully executed retainer agreements delivered - skip intake entirely

Four Layers

How We Qualify Every Ozempic Lead
Before It Reaches You

Qualified Ozempic leads are what comes out of four screens, not what goes into them. Every inbound GLP-1 claimant narrows through all four, and what reaches your CRM is what survived.

screen_01

Written Criteria

Your qualification rules become a signed document before a dollar of media runs. It is what the replacement guarantee is measured against.

Defines
Drug & use windowInjury trackDiagnostic proofYour states
screen_02

Fraud & Identity

Every inbound contact is risk-scored before a human picks up, then identity-matched through third-party verification.

Catches
BotsDuplicate identitiesDisposable numbersVPN traffic
screen_03

Live Intake Call

A trained agent confirms GLP-1 use, the injury and the diagnostic testing before the call ever reaches you. Agents are paid on whether a claimant survives your review, never on volume.

Confirms
Branded GLP-1 useDiagnosis on fileStatute intactNo prior counsel
screen_04

Delivered With the File

The claimant posts to your CRM the moment they clear, with the evidence trail attached and retrievable years later.

Delivers
Retainer formsConsent recordCall recordingReal-time post

Integrations

We Connect With the Industry's
Leading Case Management Systems.

With just under a decade and a half of experience, our work has pushed the boundaries of Legal Marketing. We seamlessly plug into the tools your firm already uses - delivering claimants directly into your existing workflow.

MyCase
Clio
LexisNexis
Litify
Filevine
SmartAdvocate
LeadDocket
See What You Receive

Here Is a Look at a Sample High Intent Ozempic Package

Every qualified claimant arrives as a complete intake summary - case criteria, injury and timeline details, verification, agreements and supporting documents - ready for your intake team to review.

Only available on live transfer and signed retainer lead packages.

Delivery Options

Three Ways to Receive Your Ozempic Leads

Every docket is different. Choose the stage where you want Ozempic and GLP-1 claimants to land — or mix delivery types as MDL 3094 and 3163 move from early filings toward settlement.

Exclusive Web Leads

Pre-screened claimants matched to your GLP-1 criteria — drug, diagnosis and use window — delivered in real time and exclusive to your firm.

No IntakePre-Screened
  • Screened against your written case criteria for each injury track
  • Third-party identity verification before delivery
  • Exclusive — never resold, recycled or sold as aged leads

Best for: firms with in-house paralegals or intake staff that want verified Ozempic volume at scale.

Live Transfers

Our non-incentivized intake agents walk the claimant through your Ozempic questionnaire by phone, then warm-transfer the call directly to your team.

Intake handled by usQualification
  • Use, diagnosis and statute confirmed before the handoff
  • Live conversation while the claimant is engaged
  • 100% connect rate — no voicemail, no callback chase

Best for: firms that want a case manager speaking with every Ozempic claimant first.

Pricing is quoted per campaign and depends on the injury track, litigation stage, your volume and how strict your criteria are.

Want premium Ozempic signed retainers for your law firm?
Where to Go Next

One Step Past the Ozempic Lead

Qualified leads are the middle of what we do, and the rest of this page covers them in detail. If you already know you want something further down the chain — claimants already signed onto your paper — that is a separate service, and you can skip straight to it.

Sample Ozempic case package, enlarged

Know the Claimant You Want

Two Injury Tracks, One Judge

The Ozempic litigation isn't one claim - it's two distinct injury sets before the same judge in the Eastern District of Pennsylvania, each reaching a different claimant with different qualifying proof and different case value. Tell us which you're building and we screen to it.

Federal MDL 3094

Gastroparesis & GI Injury

Stomach paralysis, ileus, and bowel obstruction after semaglutide or tirzepatide use.

What the Cases Allege
That the drug caused debilitating GI injury the manufacturers failed to adequately warn about on the label.
Qualifying Proof We Capture
Branded GLP-1 use and duration, the specific GI injury, and objective diagnostic testing - gastric emptying study, motility capsule, or breath test - plus hospitalization records.
Screened to the court's objective-diagnosis standard
Federal MDL 3163 · NJ State

NAION Vision Loss

Sudden, often permanent vision loss linked to GLP-1 use in emerging research.

What the Cases Allege
That GLP-1 use caused non-arteritic anterior ischemic optic neuropathy - a permanent, higher-value injury.
Qualifying Proof We Capture
A formal NAION diagnosis by an ophthalmologist or neuro-ophthalmologist, documentation of sudden painless vision loss and optic disc edema, and records ruling out mimics like giant cell arteritis.
FDA added a class-wide NAION warning in Nov 2026 - early-mover window

Ozempic, Wegovy & Mounjaro Leads

Which GLP-1 Drugs and Injuries Qualify

"Ozempic lawsuit" is shorthand for the whole GLP-1 class. We source claimants across every branded semaglutide and tirzepatide product named in the litigation, then sort each one to the right injury track before it reaches your intake team.

BrandActive ingredientManufacturerInjury tracks we screen
OzempicSemaglutide (weekly injection)Novo NordiskGastroparesis, ileus, obstruction · NAION
WegovySemaglutide (weight loss)Novo NordiskGastroparesis, ileus, obstruction · NAION
RybelsusOral semaglutideNovo NordiskGastroparesis, ileus, obstruction · NAION
MounjaroTirzepatideEli LillyGastroparesis, ileus, obstruction · NAION
ZepboundTirzepatide (weight loss)Eli LillyGastroparesis, ileus, obstruction · NAION
Trulicity, Victoza, SaxendaDulaglutide / liraglutideEli Lilly / Novo NordiskScreened to your firm's criteria

What a qualified Ozempic claimant has

  • Documented use of a branded GLP-1 (prescription or pharmacy records)
  • Injury diagnosed after starting the drug
  • Gastroparesis confirmed by a gastric emptying study or comparable objective test
  • Ileus or bowel obstruction with an ER visit or hospitalization
  • NAION diagnosed by an ophthalmologist or neuro-ophthalmologist
  • A claim inside your state's statute of limitations

What we screen out before delivery

  • Prior bariatric surgery
  • Gastroparesis or optic nerve disease diagnosed before GLP-1 use
  • Current cancer treatment
  • Symptoms only, with no testing or treatment records
  • Compounded or unbranded semaglutide only, unless your criteria accept it
  • Claimants already represented by counsel

Every rule above is adjustable. We write your criteria into the intake script and flag diagnostic status on each file so your team can see at a glance which claimants are ready to sign.

The Economics, Straight

Build Verified Inventory Before the Window Closes

GLP-1 acquisition costs are still in the window before bellwether verdicts reprice the tort. Once early trial values land, costs are widely expected to climb - and firms that built verified inventory now hold a cost advantage later arrivals won't catch.

We structure to your model and put it in writing before you spend a dollar. Every claimant is backed by our guarantee: if a lead isn't to spec, we replace it free. Qualified claimants, or you don't pay.

PPLPay-Per-Lead - you buy qualified, verified inquiries and run your own intake. Lower entry, your team carries conversion.
PPCPay-Per-Signed-Case - you buy the outcome: an Ozempic case signed retainer, litigation-ready and already cleared screening.
Why Timing Matters
Now · Nov 2026
Acquisition window open. The FDA NAION warning just landed and the MDL 3094 expert ruling is pending. Costs sit ahead of trial pricing, and statutes of limitations are running.
Next · MDL 3094 Rule 702 ruling
Expert challenges decided. Verified inventory survives; files without objective diagnosis get discounted or dismissed.
2027 · NAION general causation
Expert reports, then motions. Expert reports in spring 2027, with Rule 702 and summary judgment motions due July 2, 2027.
After causation
Bellwether trials. First trials set case values - and reprice the cost of acquiring claimants for everyone who waited.
Litigation status current as of November 2026

Where the Ozempic Lawsuit Stands: MDL 3094 & MDL 3163

Both federal GLP-1 dockets sit before Judge Karen S. Marston in the Eastern District of Pennsylvania. These are the facts shaping Ozempic case acquisition right now - ask us for the current posture before you launch.

4,082Pending GI cases in MDL 3094 (Nov 2026)
278Pending NAION cases in MDL 3163 - up from 216 in September
2Defendants: Novo Nordisk & Eli Lilly
$0Global settlement so far - no bellwether trials set yet
MDL 3094: Rule 702 ruling pendingThe court held its expert hearing September 14–18, 2026 and heard closing arguments October 13–14. Since August 2025, gastroparesis claims must be backed by a gastric emptying study or comparable objective test - the single biggest driver of lead value.
FDA adds NAION warning (Nov 9, 2026)An FDA Drug Safety Communication added a class-wide warning of potential increased NAION risk to GLP-1 labels, including semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). Expect vision-loss inquiries to climb.
MDL 3163: NAION schedule setCreated December 2025, co-lead counsel appointed February 2026, master complaint filed October 28, 2026. General causation and preemption go first, with Rule 702 and summary judgment motions due July 2, 2027.
New Jersey state court trackNew Jersey approved multicounty litigation for GLP-1 claims in November 2025, giving firms a state-court venue alongside the federal MDLs.

Full Compliance

Built on Industry Standards

Operating since 2009, we've developed processes that ensure potential leads are treated fairly and their privacy respected. On a medical-injury tort, clean provenance and verified identity protect the integrity of every file. We achieve full compliance with TCPA, HIPAA, ABA, and federal and state statutes.

GDPR Compliant
GDPR
HIPAA Compliant
HIPAA
TCPA Compliant
TCPA
CCPA Compliant
CCPA
ABA Compliant
ABA
GDPR Compliant
GDPR
HIPAA Compliant
HIPAA
TCPA Compliant
TCPA
CCPA Compliant
CCPA
ABA Compliant
ABA
Law Firm Clients

What Firms Say About Our
Mass Tort Leads

Partners who have run mass tort campaigns with us, in their own words.

Injury Case Claims have consistently exceeded our expectations with the highest quality of service and quality of case leads we have seen in a long time. It is my opinion and experience that quality is not cheap, it is PRICELESS when you build your docket.

James Curran, Marketing Director, on buying mass tort leads from Injury Case Claims

James Curran

Marketing Director

The team at ICC have an eye for details that even my own paralegals have not established. To work with an all-in-one company is a blessing in disguise because their pro plan has unlocked a ton of time for my staff and myself. The money is well worth the transparency and added value in services received.

James Evans, attorney, reviewing exclusive mass tort leads service

James Evans

Attorney

We have been doing mass torts for 21 years and have worked with quite a few marketing companies, but when we got onboard with Injury Case Claims we knew this was going to be a different experience from day one. They truly offer excellent communications throughout each step of the onboarding process, with quality of cases superb.

Richard Thomas on 21 years of mass tort case acquisition

Richard Thomas

VC Funding Specialist

I have worked with Injury Case Claims on several campaigns for which my experience has been nothing short of great. Thanks and keep up the good work so we can be partners for many years to come.

Hillary Martin, Esq., law firm client buying mass tort leads

Hillary Martin

ESQ

Keep Reading

More on GLP-1 Case Acquisition

Get Started

Get Your Ozempic Legal Leads
Quote Today

If your firm is looking for authentic Ozempic lawsuit lead generation for your GLP-1, or broader mass tort docket, give us the opportunity to earn your business.

We promise the best quality with the industry's best return policy. No other company offers investment protection like we do.

✓ Qualified Claimants Matched to Your Criteria
✓ Screened to the MDL's Diagnostic Standard
✓ 133,000+ Leads Delivered Since 2009
✓ ID-Verified Claimants
✓ Exclusive - Leads Are Never Resold
✓ TCPA, HIPAA & ABA Compliant
10:11
Recent Leads
Recent Leads Appointments Notifications

By submitting, you consent to be contacted by InjuryCaseClaims.com regarding your inquiry. This does not constitute a binding agreement. All information is handled securely and confidentially.

Real-Time Leads

Instant updates so you never miss an opportunity.

Qualified Cases

Every lead is pre-screened and ready to convert.

Maximum Results

Our technology connects you with high-value cases.

Secure & Reliable

Your data and leads are always protected.

Experience Matters

EST. 2009 ★★★★★

FAQ

Frequently Asked Questions About Ozempic Legal Leads

Everything your firm needs to know before launching your first Ozempic campaign with Injury Case Claims.

Primarily two injury sets that match the active MDLs: gastroparesis, ileus, and bowel obstruction (MDL 3094), and NAION vision loss (MDL 3163), tied to semaglutide and tirzepatide products from Novo Nordisk and Eli Lilly. We screen every lead to the right injury track and capture diagnostic status before delivery.
Exclusive to your firm. We don't resell claimants. A non-exclusive lead in a tort this competitive races three of your competitors to the phone and bleeds out before your intake team can sign it, so every claimant we deliver goes to you only - or via live transfer.
Lead Insight fraud scanning, live intake-agent screening to your custom criteria, third-party ID verification of SSN, address, and date of birth, and capture of diagnostic status - including whether the claimant has the gastric emptying study or ophthalmologic confirmation the court now requires.
Because the MDL court now rejects gastroparesis claims that lack objective testing such as a gastric emptying study. A lead that can't meet that bar isn't a case - it's wasted intake labor. We screen for diagnostic posture up front so your team isn't chasing files the court will throw out, and so your inventory holds value through Daubert and bellwether events.
Both. We structure to your model and your docket strategy - per qualified lead or per Ozempic lawsuit signed retainer - and quote it in writing before you commit a dollar. Pricing depends on injury type, verification depth, exclusivity, and volume.
Ozempic lawsuit mass tort case leads are claimants pursuing GLP-1 injury claims - primarily gastroparesis and NAION vision loss - consolidated in the federal MDLs (No. 3094 and No. 3163). As an Ozempic lawsuit lead generation partner, we source, verify, and deliver these mass tort case leads exclusively to your firm, screened to the diagnostic standard the court now requires.
Yes. Beyond qualified leads, we offer Ozempic case signed retainers - claimants who have already reviewed and executed your firm's retainer agreement before delivery. Ozempic lawsuit signed retainers cost more per file but remove intake friction almost entirely; you're buying a client, not an inquiry.
Following onboarding, Injury Case Claims usually delivers first leads within 7 days of the start of a campaign, depending on the injury track, geography, and screening criteria you set.
Your firm selects the screening requirements that give each case the best chance of success. If a lead doesn't match your criteria, we replace it at no additional cost - qualified claimants, or you don't pay.
Yes. The litigation covers the GLP-1 class, not only Ozempic. We source claimants who used Ozempic, Wegovy or Rybelsus (semaglutide, Novo Nordisk) and Mounjaro or Zepbound (tirzepatide, Eli Lilly), and screen Trulicity, Victoza and Saxenda users to your criteria. Each lead is tagged with the exact drug and injury track.
As of November 2026, MDL 3094 has 4,082 pending gastrointestinal cases before Judge Karen S. Marston in the Eastern District of Pennsylvania. The court held its Rule 702 expert hearing in September and closing arguments in October 2026, and a ruling is pending. MDL 3163, the NAION vision-loss MDL, has 278 pending cases with Rule 702 and summary judgment motions due July 2, 2027. There is no global settlement and no bellwether trial date yet.
On November 9, 2026, the FDA added a class-wide warning of potential increased NAION risk to GLP-1 drug labels, including semaglutide and tirzepatide. The warning raises public awareness, which typically lifts claimant inquiries, and it adds a regulatory data point to the NAION track. We screen every NAION lead for a formal diagnosis by an eye specialist so the file holds up regardless of how the causation fight resolves.
Pricing is quoted per campaign based on injury track, your criteria, target states, volume and delivery model - exclusive web lead, live transfer or signed retainer. NAION claimants and signed retainers cost more than GI web leads because the injury is rarer and the qualifying proof is stricter. We put pricing in writing before you spend anything, and every lead is covered by our free replacement guarantee.
Common disqualifiers include prior bariatric surgery, gastroparesis or optic nerve disease diagnosed before GLP-1 use, current cancer treatment, symptoms with no testing or treatment records, and claimants already represented. Many firms also exclude compounded semaglutide users. We screen these out at intake, and you can tighten or loosen any rule.
Yes. New Jersey approved multicounty litigation for GLP-1 claims in November 2025. We can target New Jersey residents or any other states your firm is licensed in, and route claimants to the federal MDLs or state court based on your strategy.